1.Expert consensus on digital restoration of complete dentures.
Yue FENG ; Zhihong FENG ; Jing LI ; Jihua CHEN ; Haiyang YU ; Xinquan JIANG ; Yongsheng ZHOU ; Yumei ZHANG ; Cui HUANG ; Baiping FU ; Yan WANG ; Hui CHENG ; Jianfeng MA ; Qingsong JIANG ; Hongbing LIAO ; Chufan MA ; Weicai LIU ; Guofeng WU ; Sheng YANG ; Zhe WU ; Shizhu BAI ; Ming FANG ; Yan DONG ; Jiang WU ; Lin NIU ; Ling ZHANG ; Fu WANG ; Lina NIU
International Journal of Oral Science 2025;17(1):58-58
Digital technologies have become an integral part of complete denture restoration. With advancement in computer-aided design and computer-aided manufacturing (CAD/CAM), tools such as intraoral scanning, facial scanning, 3D printing, and numerical control machining are reshaping the workflow of complete denture restoration. Unlike conventional methods that rely heavily on clinical experience and manual techniques, digital technologies offer greater precision, predictability, and efficacy. They also streamline the process by reducing the number of patient visits and improving overall comfort. Despite these improvements, the clinical application of digital complete denture restoration still faces challenges that require further standardization. The major issues include appropriate case selection, establishing consistent digital workflows, and evaluating long-term outcomes. To address these challenges and provide clinical guidance for practitioners, this expert consensus outlines the principles, advantages, and limitations of digital complete denture technology. The aim of this review was to offer practical recommendations on indications, clinical procedures and precautions, evaluation metrics, and outcome assessment to support digital restoration of complete denture in clinical practice.
Humans
;
Denture, Complete
;
Computer-Aided Design
;
Denture Design/methods*
;
Consensus
;
Printing, Three-Dimensional
2.Isogenic human pluripotent stem cell disease models reveal ABRA deficiency underlies cTnT mutation-induced familial dilated cardiomyopathy.
Bin LI ; Yongkun ZHAN ; Qianqian LIANG ; Chen XU ; Xinyan ZHOU ; Huanhuan CAI ; Yufan ZHENG ; Yifan GUO ; Lei WANG ; Wenqing QIU ; Baiping CUI ; Chao LU ; Ruizhe QIAN ; Ping ZHOU ; Haiyan CHEN ; Yun LIU ; Sifeng CHEN ; Xiaobo LI ; Ning SUN
Protein & Cell 2022;13(1):65-71
3.Study on the effect and safety of Shugan Jieyu capsules combined with olanzapine tablets for depressive symptoms in patients with schizophrenia
Yihu WANG ; Lijun CUI ; Xin PAN ; Baiping TAO
Chinese Journal of Primary Medicine and Pharmacy 2017;24(20):3053-3057
Objective To study the effect and safety of Shugan Jieyu capsules combined with olanzapine tablets in the treatment of schizophrenia,and to analyze its effects on the patients’ depressive symptoms.Methods According to the digital table,80 patients with schizophrenia were randomly divided into control group and observation group,40 cases in each group.The control group was treated with olanzapine,while the observation group was given olanzapine combined with Shugan Jieyu capsules.During the treatment,the other antidepressants,antipsychotics and mood stabilizers were prohibited.Results After treatment,the scores of CDSS,PANSS,PSQI and SQLS in the two groups were improved,and the differences were statistically significant(all P < 0.05).The CDSS score was (3.4 ± 2.5) points,PANSS score was (36.2 ± 7.5) points,PSQI score was (3.4 ± 2.5) points and SQLS total score was (79.1 ± 16.2)points in the observation group,which were all better than those in the control group[CDSS score was (2.8 ± 2.0) points,PANSS score was (40.5 ± 8.7) points,PSQI score was (5.8 ± 3.3) points and SQLS total score was (59.4 ± 19.1) points],the differences were statistically significant (t =5.942,2.368,3.666,4.975,all P < 0.05).After treatment,TCHO,TG,SBP,DBP and GLU were decreased in both two groups,but no significant differences were shown compared with before treatment(t =1.265,0.425,1.224,1.236,0.670,all P> 0.05),and there were no significant differences between the two groups (all P > 0.05).After treatment,the total effective rate of the control group(67.5%) was lower than 85.0% of the observation group,the difference was statistically significant (x2 =4.267,P < 0.05).There were no significant difference in the incidence of complications between the two groups(x2 =0.139,0.164,0.105,0.263,0.263,0.180,all P >0.05).Conclusion For the treatment of schizophrenia,combined therapy of olanzapine tablets and Shugan Jieyu capsules has significant effect and higher safety,it can improve the patients'depressive symptoms,regulate the body's metabolism and improve their sleep and life quality.
4.Animal models of brain metastasis:preparation methods and research progress
Baiping CUI ; Ping CHEN ; Anyang SUN
Chinese Pharmacological Bulletin 2016;32(3):304-309
Brain metastasis ( BM) is a common brain tumor in a-dults, originating from extracranial location in the body. There has been a growing interest in producing suitable animal models for studying BM in vivo. Current BM models take peripheral or brain route for tumor cell inoculation, including intra-cardiac or intra-carotid artery injection or orthotopic injection. Direct im-plantation of patient tumor biopsies into rodent brain bears ad-vantages of clinical relevance. This review presents a compre-hensive introduction to key elements for establishing animal mod-els of BM, with highlights on selections of suitable model ani-mals, brain-seeking tumor cell lines, reasonable inoculation routes, as well as succedent phenotyping methods. In the end, perspectives and future directions in this field are discussed.

Result Analysis
Print
Save
E-mail